| A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma (NCT01973387) | Janssen Research & Development, LLC | 2013-10-28 |
| A Long-term Extension Study of PCI-32765 (Ibrutinib) (NCT01804686) | Janssen Research & Development, LLC | 2013-09-09 |
| An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (NCT01868893) | Genentech, Inc. | 2013-08-01 |
| Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia (NCT01848145) | SCRI Development Innovations, LLC | 2013-07-01 |
| Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation (NCT01610999) | Tufts Medical Center | 2013-07-01 |
| A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion (NCT01889186) | AbbVie | 2013-06-27 |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies (NCT01796470) | Gilead Sciences | 2013-06-20 |
| Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies (NCT01871675) | SCRI Development Innovations, LLC | 2013-05-01 |
| A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor (NCT01696461) | Center for International Blood and Marrow Transplant Research | 2013-05-01 |
| A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics (NCT01841489) | Gilead Sciences | 2013-05-01 |
| BR in Patients With CLL With Comorbidities and/or Renal Dysfunction (NCT01832922) | Dartmouth-Hitchcock Medical Center | 2013-04-01 |
| Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies (NCT01799889) | Gilead Sciences | 2013-03-14 |
| Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency (NCT01787409) | Mayo Clinic | 2013-03-06 |
| Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL (NCT01728207) | Gilead Sciences | 2013-03-01 |
| Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia (NCT01944943) | The Lymphoma Academic Research Organisation | 2013-02-01 |
| Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma (NCT01716208) | Joseph Tuscano | 2013-01-14 |
| Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies (NCT01767766) | TG Therapeutics, Inc. | 2013-01-07 |
| Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia (NCT02042911) | SymBio Pharmaceuticals | 2013-01-01 |
| Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies (NCT01760655) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-12-24 |
| Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia (NCT01659021) | Gilead Sciences | 2012-12-04 |
| Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL (NCT01400685) | Massachusetts General Hospital | 2012-12-01 |
| Allogeneic Stem Cell Transplant for CLL (NCT01629511) | M.D. Anderson Cancer Center | 2012-11-21 |
| Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies (NCT01744912) | TG Therapeutics, Inc. | 2012-11-21 |
| Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512) (NCT01539291) | Gilead Sciences | 2012-10-03 |
| A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974) (NCT01650727) | Merck Sharp & Dohme LLC | 2012-10-01 |
| Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies (NCT01527045) | Fred Hutchinson Cancer Center | 2012-09-25 |
| A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT01611090) | Janssen Research & Development, LLC | 2012-09-19 |
| Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (NCT01699152) | Tragara Pharmaceuticals, Inc. | 2012-09-01 |
| Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia (NCT01849939) | University Hospital, Clermont-Ferrand | 2012-09-01 |
| Phase 1b Safety and Efficacy Study of TRU-016 (NCT01644253) | Aptevo Therapeutics | 2012-09-01 |
| A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia (NCT01627054) | NCIC Clinical Trials Group | 2012-08-27 |
| A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia (NCT01659047) | Gilead Sciences | 2012-08-01 |
| Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL (NCT01585688) | Gilead Sciences | 2012-08-01 |
| A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (NCT01682616) | AbbVie | 2012-07-25 |
| A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy (NCT01556776) | German CLL Study Group | 2012-07-20 |
| Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy (NCT01625741) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2012-07-01 |
| Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) (NCT01569295) | Gilead Sciences | 2012-06-15 |
| Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL) (NCT01557777) | AbbVie (prior sponsor, Abbott) | 2012-06-01 |
| Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) (NCT01610180) | Fondazione Progetto Ematologia | 2012-06-01 |
| Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL (NCT01703364) | Arbeitsgemeinschaft medikamentoese Tumortherapie | 2012-06-01 |
| Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) (NCT01459211) | University College, London | 2012-05-01 |
| Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (NCT01567709) | National Cancer Institute (NCI) | 2012-04-16 |
| Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning (NCT01572662) | M.D. Anderson Cancer Center | 2012-04-11 |
| Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia (NCT02034227) | Spirogen | 2012-04-01 |
| Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL (NCT01496976) | H. Lee Moffitt Cancer Center and Research Institute | 2012-03-30 |
| Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia (NCT01465230) | Yale University | 2012-03-01 |
| NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL) (NCT01486797) | TME Pharma AG | 2012-03-01 |
| Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia (NCT01500083) | Lundbeck Canada Inc. | 2012-03-01 |
| A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives (NCT01532635) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-03-01 |
| Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (NCT01497496) | H. Lee Moffitt Cancer Center and Research Institute | 2012-01-26 |
| Safety and Tolerability of HSC835 in Patients With Hematological Malignancies (NCT01474681) | Novartis Pharmaceuticals | 2012-01-09 |
| IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (NCT01534715) | ImmunoGen, Inc. | 2012-01-01 |
| Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia (NCT01515176) | National Cancer Institute (NCI) | 2012-01-01 |
| Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia (NCT01670812) | The First Affiliated Hospital with Nanjing Medical University | 2012-01-01 |
| Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia (NCT01444716) | M.D. Anderson Cancer Center | 2011-12-15 |
| Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL) (NCT01510756) | Thomas Kipps | 2011-12-01 |
| Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia (NCT01410513) | Sanofi | 2011-12-01 |
| Reduced Intensity Double Umbilical Cord Blood Transplantation (NCT01408563) | Massachusetts General Hospital | 2011-12-01 |
| Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment (NCT01521689) | Institut Paoli-Calmettes | 2011-12-01 |
| Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT01351896) | National Cancer Institute (NCI) | 2011-11-02 |
| Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL) (NCT01403246) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2011-11-01 |
| Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match (NCT01500161) | Texas Oncology Cancer Center | 2011-11-01 |
| Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation (NCT01455051) | Grupo Espanol de trasplantes hematopoyeticos y terapia celular | 2011-10-01 |
| Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG) (NCT01397149) | University of Ulm | 2011-10-01 |
| A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers (NCT01460134) | Celldex Therapeutics | 2011-10-01 |
| Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia (NCT01460238) | Dartmouth-Hitchcock Medical Center | 2011-10-01 |
| Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia (NCT01681563) | Niguarda Hospital | 2011-09-01 |
| Facing Obstacles to RDI (Relative Dose Intensity) Through Telephone Intervention Strategy (NCT01393366) | University Hospital, Toulouse | 2011-09-01 |
| Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT01369849) | National Cancer Institute (NCI) | 2011-09-01 |
| Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia (NCT01351935) | Celgene | 2011-07-18 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors (NCT01326702) | National Cancer Institute (NCI) | 2011-07-01 |
| Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies (NCT01399840) | Pfizer | 2011-06-30 |
| Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma (NCT01352312) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2011-05-25 |
| A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma (NCT01328626) | AbbVie | 2011-05-23 |
| Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia (NCT01013961) | ECOG-ACRIN Cancer Research Group | 2011-04-27 |
| Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. (NCT01353625) | Celgene | 2011-04-25 |
| Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia (NCT00962715) | M.D. Anderson Cancer Center | 2011-04-01 |
| AMG 319 Lymphoid Malignancy FIH (NCT01300026) | Amgen | 2011-04-01 |
| Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (NCT01310101) | Brno University Hospital | 2011-04-01 |
| A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (NCT01290549) | Genentech, Inc. | 2011-03-22 |
| Observational Study of Low Dose FCR in Elderly/Comorbid CLL/SLL: The Q-lite Project (NCT02156726) | Czech CLL Study Group | 2011-03-01 |
| Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (NCT01243190) | M.D. Anderson Cancer Center | 2011-03-01 |
| Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia (NCT01484015) | Wake Forest University Health Sciences | 2011-02-01 |
| A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia (NCT01558167) | German CLL Study Group | 2011-02-01 |
| Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia (NCT01657955) | Shandong Lanjin Pharmaceuticals Co.,Ltd | 2011-01-01 |
| TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation (NCT01300611) | Tarix Pharmaceuticals | 2011-01-01 |
| Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia (NCT01271283) | National Cancer Institute (NCI) | 2010-12-01 |
| Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL) (NCT01295593) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2010-12-01 |
| Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant (NCT01251575) | Fred Hutchinson Cancer Center | 2010-12-01 |
| Antiviral Treatment of Chronic Lymphocytic Leukemia (NCT01255644) | Medical University of Vienna | 2010-12-01 |
| Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza (NCT01290302) | American Regent, Inc. | 2010-11-22 |
| Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant (NCT01231412) | Fred Hutchinson Cancer Center | 2010-11-01 |
| Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia (NCT01161511) | Xencor, Inc. | 2010-09-01 |
| Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies (NCT01181258) | Masonic Cancer Center, University of Minnesota | 2010-08-01 |
| Tandem Auto-Allo Transplant for Lymphoma (NCT01181271) | Massachusetts General Hospital | 2010-08-01 |
| First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers (NCT01120457) | Bristol-Myers Squibb | 2010-08-01 |
| Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (NCT01199575) | University of California, San Diego | 2010-08-01 |
| A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL) (NCT01087151) | Genentech, Inc. | 2010-08-01 |
| Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL (NCT01173679) | Massachusetts General Hospital | 2010-07-01 |
| A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL) (NCT01005979) | Emory University | 2010-07-01 |